Phathom Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Phathom Pharmaceuticals, Inc. (PHAT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-334.33-201.59-197.72-143.88-129.07
Depreciation & Amortization0.800.580.620.520.32
Stock Based Compensation24.0545.0324.1316.815.84
Change in Working Capital-15.30-13.645.44-27.3251.72
Change in Accounts Receivable-37.16-1.640.000.000.00
Change in Inventory-6.14-9.440.000.000.00
Change in Accounts Payable34.946.418.68-9.7924.01
Change in Other Working Capital-6.9332.06-3.245.4127.71
Other Operating Activities55.8232.0618.895.410.23
Net Cash from Operating Activities-266.77-137.58-146.53-148.46-69.69
Investing Activities
Capital Expenditures-0.14-1.63-1.04-0.33-1.04
Net Cash from Investing Activities-0.14-1.63-1.04-0.33-1.04
Financing Activities
Debt Repayment59.400.000.00-54.130.00
Common Stock Issued123.37155.4624.601.9489.46
Other Financing Activities1.60172.6895.450.000.00
Net Cash from Financing Activities182.77367.58120.0444.71114.46
Summary
Net Change in Cash-84.13228.37-27.53-104.0843.73
Cash at Beginning of Period384.26155.89183.42287.500.00
Cash at End of Period300.13384.26155.89183.420.00
Free Cash Flow-266.91-139.21-147.57-148.79-70.73
Supplemental Disclosures
Interest Paid17.2911.137.034.073.46